AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

The aHUS therapy landscape is on the cusp of disruption-with emerging oral drugs and biosimilars reshaping market dynamics ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

The ultomiris market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

Ultomiris (ravulizumab-cwvz) is a brand-name injection that’s prescribed for certain rare diseases. As with other drugs, Ultomiris can cause side effects, such as upper respiratory tract ...

Ultomiris (ravulizumab-cwvz) is a prescription drug that’s used to treat myasthenia gravis and other conditions. Ultomiris’s cost may depend on factors such as your dosage and whether you have ...

AstraZeneca AZN announced that the FDA has approved its drug Ultomiris for a new rare neurological disease. The approval for long-acting C5 complement inhibitor Ultomiris is for the treatment of ...

WILMINGTON, Del., March 25, 2024--(BUSINESS WIRE)--ULTOMIRIS ® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the ...